In AML, talazoparib is currently under investigation in combination with several therapies, including decitabine in untreated, relapsed, or refractory AML (ClinicalTrials.gov Identifier: NCT02878785), as well as with antibody-drug conjugate gemtuzumab ozogamicin in CD33-positive relapsed or refractory AML (NCT04207190). The gene discussed is CD33; the disease is acute myeloid leukemia.